FDA Greenlights J&J's Oral Psoriasis Pill

• Icotyde demonstrated superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials
• The drug blocks the IL-23 protein involved in inflammatory responses and is being studied for ulcerative colitis, psoriatic arthritis, and Crohn's disease
• J&J aims to position Icotyde as the 'first-line systemic therapy' for psoriasis patients, competing against Bristol's Sotyktu and AbbVie's Skyrizi

Summary

Key Development: The FDA has approved Johnson & Johnson's oral psoriasis pill, branded as Icotyde, marking a significant expansion into the psoriasis treatment market. The approval covers moderate-to-severe plaque psoriasis for adults and pediatric patients aged 12 and older weighing at least 40 kg.

Strategic Context: The drug's approval is strategically important for J&J as its blockbuster injectable Stelara faces growing competition from low-cost biosimilars. Icotyde is developed in partnership with Protagonist Therapeutics.

Competitive Landscape: Icotyde will compete directly with Bristol Myers Squibb's Sotyktu and AbbVie's Skyrizi in the psoriasis market. Wall Street analysts project "blockbuster potential" for the once-daily oral medication. J&J has demonstrated competitive advantage through late-stage trials showing superior skin clearance compared to Bristol's Sotyktu in head-to-head studies.

Mechanism of Action: The drug blocks the IL-23 protein involved in inflammatory responses, similar to AbbVie's Skyrizi and J&J's own Tremfya injectable. The oral format offers patients a more convenient alternative to injectable treatments.

Market Positioning: J&J's global head of immunology, David Lee, stated the company expects Icotyde to become "the first-line systemic therapy for psoriasis patients," citing patient demand for complete skin clearance, favorable safety profile, and once-daily dosing convenience.

Pipeline Potential: J&J is also studying icotrokinra (the drug's chemical name) for additional indications including ulcerative colitis, psoriatic arthritis, and Crohn's disease, suggesting broader revenue opportunities.

Missing Information: Pricing and availability details were not disclosed at the time of approval.